Lizhu Pharmaceutical (01513): The marketing license application for leconchitazumab injection was accepted by the China Drug Administration

Zhitongcaijing · 2d ago

Zhitong Financial App News, Lizhu Pharmaceutical (01513) announced that the company's holding subsidiary, Zhuhai Lizhudan Antibiotic Technology Co., Ltd. (Lizhumab) received the “Notice of Acceptance” (acceptance number: CXSS2500144) approved and issued by the State Drug Administration, and the registration and marketing license application for domestically produced drugs for the domestic production of laconchitazumab injection jointly developed by Lizhumab and Beijing Xinkanghe Biomedical Technology Co., Ltd. was accepted by the State Drug Administration.